中国经济网北京4月11日讯 药易购(300937.SZ)昨晚披露2024年年报。2024年，公司实现营业收入43.81亿元，同比减少1.12%；归属于上市公司股东的净利润1635.82万元，同比减少72.52%；扣除非经常性损益后的净利润1236.97万元，同比减少77.10%；经营活动产生的现金流量净额1.28亿元，同比增长210.58%。

药易购于2021年1月27日在深交所创业板上市，发行数量为2391.6671万股，发行价格为12.25元/股，保荐机构为申万宏源证券承销保荐有限责任公司，保荐代表人为刘强、杨晓。药易购募集资金总额为2.93亿元，扣除发行费用后，募集资金净额为2.49亿元。

药易购最终募集资金净额较原计划少1.96亿元。招股说明书显示，公司拟募集资金4.45亿元，分别用于合纵医药电商物流中心项目、药易达物流配送体系建设项目、电子商务平台优化升级项目、补充流动资金项目。

公司上市发行费用为4350.59万元，其中保荐机构申万宏源获得承销保荐费2358.49万元。

海量资讯、精准解读，尽在新浪财经APP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.